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In patients with peri-implant mucositis and peri-implantitis, what is the efficacy of nonsurgical (i.e. referring to
peri-implant mucositis and peri-implantitis) and surgical (i.e. referring to peri-implantitis) treatments with alternative
or adjunctive measures on changing signs of inflammation compared with conventional nonsurgical (i.e.
mechanical/ultrasonic debridement) and surgical (i.e. open flap debridement) treatments alone? After electronic
database and hand search, a total of 40 publications (reporting on 32 studies) were finally considered for the
qualitative and quantitative assessment. The weighted mean changes (WM)/ and WM differences (WMD) were
estimated for bleeding on probing scores (BOP) and probing pocket depths (PD) (random effect model).
Peri-implant mucositis: WMD in BOP and PD reductions amounted to −8.16 % [SE = 4.61] and −0.15 mm [SE = 0.13],
not favouring adjunctive antiseptics/antibiotics (local and systemic) over control measures (p > 0.05). Peri-implantitis
(nonsurgical): WMD in BOP scores amounted to −23.12 % [SE = 4.81] and −16.53 % [SE = 4.41], favouring alternative
measures (glycine powder air polishing, Er:YAG laser) for plaque removal and adjunctive local antibiotics over
control measures (p < 0.001), respectively. Peri-implantitis (surgical): WMD in BOP and PD reductions did not favour
alternative over control measures for surface decontamination. WM reductions following open flap surgery
(±resective therapy) and adjunctive augmentative therapy amounted to 34.81 and 50.73 % for BOP and 1.75 and
2.20 mm for PD, respectively. While mechanical debridement alone was found to be effective for the management
of peri-implant mucositis, alternative/adjunctive measures may improve the efficacy over/of conventional
nonsurgical treatments at peri-implantitis sites. Adjunctive resective and/or augmentative measures are promising;
however, their beneficial effect on the clinical outcome of surgical treatments needs to be further investigated.Review
Background
Peri-implant mucositis describes an inflammatory lesion
that resides in the soft tissues compartment, while at
peri-implantitis sites, this lesion has extended and also
affects the implant supporting bone [1]. The 11th
European Workshop on Periodontology has pointed to
an “estimated weighted mean prevalence of peri-
implant mucositis and peri-implantitis of 43 and 22 %,
respectively” [2].* Correspondence: Frank.Schwarz@med.uni-duesseldorf.de
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professionally administered plaque removal is a key
strategy for the prevention and management of peri-
implant diseases [6]. In previous years, several alternative or
adjunctive measures (e.g. local antibiotics, air polishing,
laser application) have been proposed to improve the effi-
cacy of nonsurgical treatment approaches [7–9]. At peri-
implantitis sites, surgical protocols may involve different
decontamination protocols, that may also be combined
with resective (e.g. pocket elimination, bone re-contouring,
implantoplasty) and/or augmentative approaches (e.g. bone
substitutes or autografts with or without a supporting bar-
rier membrane) [7, 10]. Accordingly, there is a need to
identify the most effective interventions for the treatment
of peri-implant diseases.
The aim of this systematic review was therefore to ad-
dress the following focused question: in patients with
peri-implant mucositis and peri-implantitis, what is the
efficacy of nonsurgical (i.e. referring to peri-implant
mucositis and peri-implantitis) and surgical (i.e. refer-
ring to peri-implantitis) treatments with alternative or
adjunctive measures on changing signs of inflammation
compared with conventional nonsurgical and surgical
treatments alone?
Methods
This systematic review was structured and conducted ac-
cording to the preferred reporting items of the PRISMA
statement [11].
Focused question
The focused question serving for literature search was
structured according to the PICO format [12]: “In patients
with peri-implant mucositis and peri-implantitis, what is
the efficacy of nonsurgical (i.e. referring to peri-implant
mucositis and peri-implantitis) and surgical (i.e. refer-
ring to peri-implantitis) treatments with alternative or
adjunctive measures on changing signs of inflammation
compared with conventional nonsurgical and surgical
treatments alone?”.
Population: patients with peri-implant mucositis and
peri-implantitis based on case definitions used in re-
spective publications
Intervention: alternative or adjunctive measures to
nonsurgical and surgical treatments
Comparison: conventional measures for nonsurgical
and surgical treatments
Outcome: changes in peri-implant mucosal inflammation
Search strategy
The PubMed database of the U.S. National Library of
Medicine and the Web of Knowledge of Thomson
Reuters were used as electronic databases to perform a
systematic search for relevant articles published in thedental literature between 1992 up to April 30, 2015. A
commercially available software program (Endnote X7,
Thomson, London, UK) was used for electronic title
management. Screening was performed independently
by two authors (F.S. and A.S.). Disagreement regarding
inclusion during the first and second stage of study se-
lection was resolved by discussion.
The combination of key words (i.e. Medical Subject
Headings MeSH) and free text terms included:
“treatment” OR “nonsurgical treatment” OR “non-surgi-
cal treatment” OR “surgical treatment” OR “regenerative
treatment” OR “augmentative treatment” OR “resective
treatment” OR “reconstructive treatment” OR “therapy”
OR “nonsurgical therapy” OR “non-surgical therapy” OR
“surgical therapy” OR “regenerative therapy” OR “augmen-
tative therapy” OR “resective therapy” OR “reconstructive
therapy” OR “antiseptic treatment” OR “antibiotic treat-
ment” OR “adjunctive treatment” OR “antiseptic therapy”
OR “antibiotic therapy” OR “adjunctive therapy”
AND
“peri-implant disease” OR “periimplant disease” OR
“peri-implant infection” OR “periimplant infection” OR
“mucositis” (MeSH) OR “peri-implant mucositis” OR
“periimplant mucositis” OR “Periimplantitis” (MeSH)
OR “peri-implantitis”.
Electronic search was complemented by a hand search
of the following journals:
Clinical Implant Dentistry and Related Research;
Clinical Oral Implants Research; International Journal
of Oral and Maxillofacial Implants; Journal of Clinical
Periodontology; Journal of Periodontology. Finally, the
references of all selected full-text articles and related
reviews were scanned. If required, the corresponding
authors were contacted and requested to provide
missing data or information.
Study inclusion and exclusion criteria
During the first stage of study selection, the titles and
abstracts were screened and evaluated according to the
following inclusion criteria:
1) English language.
2) Prospective randomized controlled (RCT), or non-
randomized controlled (CCT) studies (split-mouth
or parallel group designs) in humans comparing
alternative (i.e. for biofilm removal) or adjunctive
measures (i.e. for biofilm removal, or adjunctive
antiseptic/antibiotic therapy, or regenerative/
resective approaches) to conventional nonsurgical
(i.e. mechanical/ultrasonic debridement) or surgical
(i.e. open flap debridement) treatments.
3) Data on the clinical changes in mucosal
inflammation (i.e. bleeding scores) and probing
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to peri-implant mucositis and peri-implantitis) or
surgical (referring to peri-implantitis) treatments in
respective groups.
At the second stage of selection, all full-text articles
identified during the first stage were acquired. During this
procedure, the pre-selected publications were evaluated
according to the following exclusion criteria:
1) Inclusion of less than five patients
2) Inadequate case definition [13]
3) Lack of clinical data on the changes in mucosal
inflammation and PDQuality assessment of selected studies
A quality assessment of all selected full-text articles
was performed according to the Cochrane collabora-
tions tool for assessing risk of bias (low, high, unclear)
including the following domains: random sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment,
and incomplete outcome data [14]. Quality assessment
was performed in two different phases. In particular,
during phase I, quality assessment was based on the
published full-text article performed independently by
both authors. In phase II, disagreements were resolved
by discussion.Data extraction and method of analysis
A data extraction template was generated and based on
the study design, population, case definition, observation
period, interventions, comparisons, and primary and sec-
ondary outcomes as well as the study quality. For data
analysis, the bleeding index (BI)/bleeding on probing
(BOP) and PD scores after respective healing periods were
defined as primary outcomes. Secondary outcomes in-
cluded changes in marginal bone levels, immunological/
microbiological parameters and the resolution of peri-
implant diseases, based on case definitions used in re-
spective publications. RCTs and CCTs not implementing
appropriate control measures but reporting on changes in
primary outcomes were used for the estimation of the
overall efficacy of treatments.
Heterogeneity between RCTs, meta-analysis (i.e.
weighted mean changes/differences and 95 % confidence
intervals, random effect model to account for potential
methodological differences between studies), forest plots
and publication bias (Egger’s regression to quantify the
bias captured by funnel plots) were assessed using a com-
mercially available software program (Comprehensive
Meta-Analysis V2, Biostat, Englewood, NJ 07631 USA).Results
Study selection
A total of 368 potentially relevant titles and abstracts were
found during the electronic and manual search. During
the first stage of study selection, 319 publications were
excluded based on title and abstract. For the second phase,
the complete full-text articles of the remaining 49 publica-
tions were thoroughly evaluated. A total of 19 papers had
to be excluded at this stage because they did not fulfil the
inclusion criteria of the present systematic review
(Table 1).
Finally, a total of 40 publications (reporting on 32
studies) were considered for the qualitative and quanti-
tative assessment (Fig. 1).
Quality and risk of bias assessment of selected studies
The review author’s judgement about each risk of bias
item for each included RCT is presented in Table 2. In
particular, the percentages across all included studies for
high, low and unclear risk of bias items were 34.1, 54.8
and 11.1 %, respectively (Table 2).
Subdivision of selected studies
All selected publications were subdivided according to
differences in the treatment protocol:
o Nonsurgical treatment of peri-implant mucositis—-
alternative or adjunctive measures for biofilm removal
(2 RCTs and 1 CCT) (Table 3)
o Nonsurgical treatment of peri-implant mucositis—-
adjunctive antispectic therapy (3 RCTs) (Table 4)
o Nonsurgical treatment of peri-implant mucositis—-
adjunctive antibiotic therapy (2 RCTs) (Table 5).
o Nonsurgical treatment of peri-implantitis—alternative
measures for biofilm removal (6 RCTs) (Table 6)
o Nonsurgical treatment of peri-implantitis—adjunctive
antiseptic therapy (1 RCT) (Table 7)
o Nonsurgical treatment of peri-implantitis—adjunctive
antibiotic therapy (4 RCTs) (Table 8)
o Surgical treatment of peri-implantitis—alternative
measures for surface decontamination (3 RCTs and 1
CCT) (Table 9)
o Surgical treatment of peri-implantitis—adjunctive
resective therapy (1 RCT) (Table 10)
o Surgical treatment of peri-implantitis—adjunctive
augmentative therapy (4 RCTs, 4 CCTs) (Table 11)
Nonsurgical treatment of peri-implant mucositis
The case definitions markedly differed among the stud-
ies investigated. While three studies considered mucosal
inflammation in the absence of radiographic bone loss
[15–17], four studies also accepted a bone resorption of
up to 3 mm for defining peri-implant mucositis [18–21].
Moreover, these studies used several clinical parameters
Table 1 Excluded clinical studies at the second stage of selection and the reason for exclusion
Publication Reason for exclusion
Lavigne et al. [63] Experimental sites without BOP at baseline
Ciancio et al. [64] Homecare plaque control protocol
Felo et al. [65] Homecare plaque control protocol
Bach et al. [66] Lack of clinical data defined for the present systematic review
Dörtbudak et al. [67] Lack of a conventional control treatment
Khoury and Buchmann [68] Changes in mucosal inflammation not reported
Roos-Jansaker et al. [69] Observational study
Duarte et al. [70] Observational study reporting on the same study population as [71]
Maximo et al. [71] Observational study
Ramberg et al. [72] Homecare plaque control protocol
Corbella et al. [73] Prevention of peri-implant diseases
Heitz-Mayfield et al. [74] Homecare plaque control protocol
Costa et al. [5] Observational study
De Angelis et al. [75] Lack of subgroup analyses
Salvi et al. [76] Observational study
Deppe et al. [59] Observational study
De Siena et al. [77] Homecare plaque control protocol
McKenna et al. [78] Case definition not reported
Flichy-Fernandez et al. [79] Cross-over study design
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hygiene instructions (OHI) and defined different inter-
vals for maintenance care. Despite significant improve-
ments in all of the clinical parameters investigated, test
(i.e. alternative or adjunctive methods for biofilm removal,
adjunctive antiseptic therapy, or adjunctive antibiotic ther-
apy) and control treatments were commonly associated
with residual gingival index (GI), BI, and/or BOP scores at
3 to 12 months after therapy (Tables 3, 4 and 5).Alternative or adjunctive measures for biofilm removal
Three studies reported on alternative or adjunctive mea-
sures for biofilm removal (Table 3).
In particular, one RCT and one CCT compared the clin-
ical efficacy of adjunctive air polishing (glycine powder) to
OHI and mechanical debridement using either ultrasonic
scalers or hand instruments [15, 18]. Both test and control
groups were associated with significant improvements in
mean BI and PD scores after therapy. When evaluating
absolute values at 6 months, mean BI and PD scores were
significantly lower following adjunctive air polishing to
teflon curettes [18]. One RCT compared a repeated (3 and
6 months) monotherapy using an air abrasive device to
ultrasonic scaling. After a healing period of 12 months,
both groups revealed comparable BOP reductions and
frequencies of diseased sites [21] (Table 3).Adjunctive antiseptic therapy Three RCTs reported on
the adjunctive antispectic therapy to OHI and mechan-
ical debridement [17, 20, 22] (Table 4).
In particular, one RCT assessed the adjunctive appli-
cation of phosphoric acid gel to carbon curettes and
rubber cup polishing, which was provided once every
month in both groups. At 5 months, test sites revealed
a significantly higher reduction in mean gingival index
(GI) (modified, but not specified) and colony-forming
units when compared with control sites, respectively
[22]. Porras et al. [20] compared OHI + mechanical de-
bridement with and without local pocket irrigation
using chlorhexidine digluconate (CHX) + topical CHX
gel application + CHX mouthwash (twice for 10 days).
At 3 months, mean mucosal bleeding (mBI), BOP
scores and microbiological parameters did not signifi-
cantly differ between test and control groups. However,
the test group revealed a significantly higher change in
mean PD scores [20]. In another RCT, topical CHX gel
application + full mouth disinfection + CHX mouthrinse
(2×/day) and tonsil spraying (1×/day) for 14 days was
compared with OHI + mechanical debridement (plastic
scaler + polyetheretherketone-coated ultrasonic instru-
ments) + full mouth scaling alone. While both treat-
ment procedures were associated with significant PD
reductions at 8 months, the BOP scores did not signifi-
cantly differ to baseline in both groups [17] (Table 4).
Fig. 1 Flow diagram of literature search and inclusion
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on the adjunctive antibiotic (i.e. local or systemic) ther-
apy to OHI and mechanical debridement [16, 19]
(Table 5).
In particular, one RCT compared the adjunctive local
delivery of tetracycline HCl (25 %) fibres for 10 days
(test) to mechanical debridement alone (control). A
complete or partial fibre loss was noted at three im-
plants after 7 to 10 following application. While test sites
were associated with marked BOP improvements, con-
trol sites revealed a further increase of BOP scores at
3 months [16]. In another RCT, a total of 45 patients
were randomly allocated to either OHI +mechanical de-
bridement (titanium curettes + rubber polishing) + sys-
temic antibiotic medication (Azithromycin® 500 mg day
1 and 250 mg days 2–4) (test), or OHI +mechanical de-
bridement alone (control). The subject-based, per-
protocol analysis at 6 months did not reveal any signifi-
cant differences between test and control groups for all
clinical and microbiological parameters investigated [19]
(Table 5).Nonsurgical treatment of peri-implantitis
In all studies investigated, peri-implantitis was commonly
defined by BOP and a radiographic bone loss. However,
the reference points (i.e. baseline radiographs) and thresh-
olds used to identify bone level changes were either not
specified [23–25] or exhibited large variations [26–34].
Radiographic bone level changes as treatment outcome
were merely assessed in three studies [28–30].
Despite significant improvements in all of the clinical
and microbiological parameters investigated, test (i.e.
alternative methods for biofilm removal, adjunctive
antiseptic therapy, or adjunctive antibiotic therapy) and
control treatments were commonly associated with
residual BI and BOP scores at 3 to 12 months after
therapy (Tables 6, 7 and 8).
Alternative measures for biofilm removal Six RCTs
(corresponding to 7 publications) reported on the effi-
cacy of alternative measures for biofilm removal
(Table 6). In particular, two studies employed the same
type of an ultrasonic device used with a hydroxyapatite











Schenk et al. [16] ? − − − +
Strooker et al. [22] ? − − − +
Porras et al. [20] ? − − + −
Büchter et al. [26] + − − ? +
Romeo et al. [42, 57] ? − − − +
Karring et al. [28] ? + − + +
Schwarz et al. [25] + − − + +
Renvert et al. [32] + + − + +
Schwarz et al. [24] + − − + +
Schwarz et al. [48, 51, 54] + − − + +
Renvert et al. [29] + + − + +
Renvert et al. [31] + ? − + +
Renvert et al. [30] + − − + +
Sahm et al.; John et al.
[27, 33]
+ − − + +
Thone-Mühling et al. [17] − ? − − +
Hallström et al. [19] + ? − − +
Schwarz et al. [49, 50, 52] + − − + +
Aghanzadeh et al. [43] ? ? − + +
Machtei et al. [23] + + ? + +
Wohlfahrt et al. [55, 58] + + − + +
deWaal et al. [38] + + ? + +
McKenna et al. [78] + − + + −
Schär et al.; Bassetti et al.
[34, 37]
+ − − +
deWaal et al. [39] + + ? + +
Ji et al. [15] + ? − + +
Papadopoulos et al. [41] + − − + +
Riben Grundström et al.
[21]
+ + − + +
+ low, − high, ? unclear
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erbium-doped yttrium aluminum garnet (Er:YAG) laser
monotherapy [24, 25] and two publications on glycine
powder air polishing [27, 33]. One study compared
Er:YAG laser monotherapy versus air polishing [30].
At 3 months after therapy, nonsurgical ultrasonic de-
bridement was associated with a reduction in mean BOP
scores, whereas these values further increased at control
sites (i.e. carbon fibre curettes). However, these differ-
ences, as well as those noted for mean PD and radio-
graphic bone level changes, did not reach statistical
significance between groups [28]. Similarly, when compar-
ing ultrasonic scaling with mechanical debridement using
titanium curettes, Renvert et al. [31] also failed to identifyany significant between group differences in mean BI and
PD reductions at 6 months. Furthermore, both procedures
did not reduce bacterial load [35] (Table 6).
In two RCTs, the efficacy of Er:YAG laser monother-
apy was compared to that of mechanical debridement
using carbon fibre curettes + adjunctive local antiseptic
CHX irrigation/application [24, 25]. After 6 months of
healing, Er:YAG laser application was associated with
significantly lower mean BOP scores than the control
treatment. However, these improvements failed to
reach statistical significance at 12 months, particularly
at advanced sites [24, 25] (Table 6). In one RCT, glycine
powder air polishing resulted in a significantly higher
reduction of mean BOP scores at 3, 6, and 12 months
Table 3 Included studies—nonsurgical treatment of peri-implant mucositis: alternative or adjunctive measures for biofilm removal
Publication Design Population Case definition Period Test Control Mean (SD) outcome
Ji et al. [15] RCT,
parallel
24 patients PD ≥4 mm, BOP + no radiographic
bone loss compared with baseline (i.e.
immediately after prosthesis installation)
3 months OHI +mechanical debridement (ultrasonic
scaler with carbon fibre tips) + air abrasive




scaler with carbon fibre
tips)
Test
33 implants BI: 1.4 (0.57) (BL) to 1.1




BI: 1.7 (0.93) (BL) to 1.1
(0.98) (3 months, implant
level)
1 implant system Sites without bleeding:
29.3 %
PD: 3.6 (0.47) (BL) to 3.2
(0.48) mm (3 months,
subject level)
Control
BI: 1.5 (0.65) (BL) to 1.0
(0.85) (3 months, subject
level)
BI: 1.7 (1.0) (BL) to 0.9 (1.1)
(3 months, implant level)
Sites without bleeding:
42 %
PD: 3.5 (0.5) (BL) to 3.1






30 patients BOP or spontaneous bleeding with
local swelling
6 months OHI +mechanical debridement Teflon









PD ≤3.5 mm PD: 3.0 (0.4) (BL) to 2.4
(0.5) mm (6 months,
subject level)




PD: 2.9 (0.4) (BL) to 3.0
(0.6) mm (6 months,
subject level)
9 patients did not present














Table 3 Included studies—nonsurgical treatment of peri-implant mucositis: alternative or adjunctive measures for biofilm removal (Continued)
BI and PD scores sign.







37 patients PD ≥4 mm, BOP + with or without
suppuration
12 months OHI + air abrasive device, glycine powder OHI +mechanical
debridement (ultrasonic





Bone loss ≤2 mm from implant
shoulder
Repeated treatment at 3 and 6 months Repeated treatment at 3
and 6 months
BOP: 43.9 (7.3) (BL) to 12.1
(3.8) % (12 months, subject
level)
Test N = 19 Number of diseased sites
(pocket depth ≥4 mm
with bleeding/
suppuration)
Control N = 18 38 % (BL) to 8 %
(12 months, subject level)
Control
BOP: 53.7 (7.9) (BL) to 18.6
(6.4) % (12 months, subject
level)
Number of diseased sites
(pocket depth ≥4 mm
with bleeding/
suppuration)
52 % (BL) to 17 %
(12 months, subject level)
No significant differences
between groups for either
reduction of
BOP or of diseased sites














Table 4 Included studies—nonsurgical treatment of peri-implant mucositis: adjunctive antiseptic therapy












Not reported 5 months Supra-/subgingival scaling
(carbon curettes) +
polishing (rubber cup) +
phosphoric acid gel
(35 %) in sulcus for 1 min
Supra-/subgingival scaling
(carbon curettes) + polishing
(rubber cup) Once every month
Test (subject level)
Once every month BOP: 30.5 (27.5) (BL) to 9.7
(10.97) % (5 months)
GI: 0.92 (0.75) (BL) to 0.34
(0.38) (5 months)
PD: 2.97 (0.68) (BL) to 2.34
(0.54) mm (5 months)
Control (subject level)
BOP: 29.2 (29.44) (BL) to 14.3
(22.47) % (5 months)
GI: 0.82 (0.8) (BL) to 0.57 (0.6)
(5 months)
PD: 2.83 (0.57) (BL) to 2.48
(0.49) mm (5 months)
Sign. between group
difference in mean GI values






16 patients Supra- and
subgingival plaque
3 months OHI + mechanical cleansing
(plastic scaler, rubber cups,
polishing paste) + local irrigation
CHX (0.12 %) and topical
CHX gel application + 0.12 %
CHX mouthrinse twice for 10 days
OHI + mechanical cleansing
(plastic scaler, rubber cups,
polishing paste)
mBI and BOP (%) scores: no
sign. differences between
groups at 1 and 3 months






cp Ti (HA-coated Ti)
Test: 3.27 (0.81) (BL) to 2.71
(0.70) mm (3 months)
Control: 3.48 (0.61) (BL) to 2.55
(0.72) mm (3 months)
Changes in mean PD between
test and control groups at
3 months were statistically






















11 patients BOP + and/or GI ≥1
absence of
radiographic bone
loss during the last
2 years
8 months OHI + mechanical cleansing (plastic scaler and
polyetheretherketone-coated ultrasonic instruments) +
topical CHX gel application once + full mouth
disinfection (deep scaling in one session + CHX
disinfection of tongue and tonsils) + 0.2 % CHX
mouthrinse 2×/day and tonsil spraying 1×/day for 14 days
OHI + mechanical cleansing
(plastic scaler and
polyetheretherketone-coated
ultrasonic instruments) + full
mouth scaling in one session
Test
36 implants BOP: 0.22 (0.11) (BL) to 0.16
(0.09) % (8 months)
2 implant types GI: 0.6 (0.24) (BL) to 0.44 (0.23)
(8 months)
PD: 3.4 (0.68) (BL) to 2.82
(0.59) mm (8 months)
Control
BOP: 0.17 (0.19) (BL) to 0.17
(0.11) % (8 months)
GI: 0.62 (0.36) (BL) to 0.43
(0.37) (8 months)
PD: 3.49 (0.78) (BL) to 2.84
(0.64) mm (8 months)
Bacterial recolonization over
time














Table 5 Included studies—nonsurgical treatment of peri-implant mucositis: adjunctive antibiotic therapy







8 patients PD >4 mm BOP on at
least 1 site per implant ±
mucosal hyperplasia no
radiographic bone loss
3 months Supra-/subgingival scaling (steel curettes) +
polishing (rubber cup) + locally delivered
tetracycline HCl (25 %) fibre for 10 days
+0.2 % CHX mouthrinse twice for 10 days
Supra-/subgingival scaling
(steel curettes) + polishing
(rubber cup) + +0.2 % CHX
mouthrinse twice for 10 days
ΔBOP (3 months, subject
level)
24 implants Test: −17 ± 25 %




Control: 15 ± 37 %
PD/CAL values without









45 patients PD ≥4 mm BOP + and/or
pus
6 months OHI +mechanical cleansing
(titanium curettes + rubber
cups + polishing paste) +
Azithromycin® 500 mg day 1
and 250 mg days 2–4
OHI +mechanical cleansing
(titanium curettes + rubber
cups + polishing paste)
Test
3 implant systems Radiographic bone loss
≤2 mm
BOP: 82.6 (24.4) (BL) to 27.3
(18.8) % (6 months, subject
level)
PD at worst site: 5.5 (0.8)
(BL) to 4.1 (1.2) mm
(6 months, subject level)
Control
BOP: 80.0 (25.0) (BL) to 47.5
(32.3) % (6 months, subject
level)
PD at worst site: 5.7 (0.8)
(BL) to 4.9 (1.1) mm
(6 months, subject level)
Odds ratio of a positive
treatment outcome (PD≤
4.0 mm and BOP≤ 1) was
4.5:1 (test vs. control)
Comparable reductions in
bacterial counts














Table 6 Included studies—nonsurgical treatment of peri-implantitis: alternative measures for biofilm removal
Publication Design Population Case definition Period Test Control Mean (SD) outcome
Karring et al. [28] 11 patients PD ≥5 mm, BOP + bone
loss >1.5 mm and exposed
threads
3 months OHI + ultrasonic device with
hydroxyapatite fluid polish






BOP: 63.6 (BL) to 36.4 %
(3 months, subject level)
PD: 5.8 (1.1) (BL) to 5.8 (1.2) mm
(3 months, subject level)
Radiographic bone level changes: 0.1
(0.5)mm (3 months, subject level)
Control
BOP: 72.7 (BL) to 81.8 %
(3 months, subject level)
PD: 6.2 (1.6) (BL) to 6.3 (2.2) mm
(3 months, subject level)
Radiographic bone level changes:
−0.2 (1.2) mm (3 months, subject
level)
Absence of BOP at 7/11 (test) and
2/11 (control) sites
Schwarz et al. [25] RCT,
parallel
20 patients PD ≥4 mm, BOP + and pus 6 months OHI + Er:YAG laser device
(cone-shaped glass fibre tip)
at 12.7 J/cm2
OHI + mechanical debridement
(plastic curettes), 0.2 % CHX
pocket irrigation and 0.2 %
CHX gel
Test
32 implants rough and
medium-rough surfaces
Radiographic bone loss BOP: 83.2 (17.2) (BL) to 31.1
(10.1) % (6 months, subject level)
PD: 5.4 (1.2) (BL) to 4.6 (1.1) mm
(6 months, subject level)
Control
BOP: 81.3 (19.0) (BL) to 58.3
(16.9) % (6 months, subject level)
PD: 5.5 (1.5) (BL) to 4.8 (1.4) mm
(6 months, subject level)
BOP scores at 6 months were















Table 6 Included studies—nonsurgical treatment of peri-implantitis: alternative measures for biofilm removal (Continued)
Schwarz et al. [24] RCT,
parallel
20 patients PD ≥4 mm, BOP + and pus 12 months OHI + Er:YAG laser device
(cone-shaped glass fibre tip)
at 12.7 J/cm2
OHI + mechanical debridement
(plastic curettes), 0.2 % CHX
pocket irrigation and 0.2 %
CHX gel
Test
40 implants rough and
medium-rough surfaces
Radiographic bone loss Moderately deep sites
BOP: 81.7 (6.7) (BL) to 35.0 (6.3) %
(12 months, subject level)
PD: 4.5 (1.4) (BL) to 4.0 (0.1) mm
(12 months, subject level)
Deep sites
BOP: 79.9 (4.8) (BL) to 55.0 (6.5) %
(12 months, subject level)
PD: 5.9 (0.1) (BL) to 5.4 (0.1) mm
(12 months, subject level)
Control
Moderately deep sites
BOP: 81.6 (5.2) (BL) to 53.3 (7.3) %
(12 months, subject level)
PD: 4.4 (0.2) (BL) to 4.3 (0.1) mm
(12 months, subject level)
Deep sites
BOP: 88.3 (3.5) (BL) to 66.6 (5.5) %
(12 months, subject level)
PD: 5.9 (0.3) (BL) to 5.5 (0.2) mm
(12 months, subject level)
No significant differences
between groups at 12 months
Renvert et al. [31] RCT,
parallel
31 patients PD ≥4 mm, BOP + and/or
pus









Bone loss <2.5 mm BI: 1.7 (0.6) (BL) to 1.2 (0.7)
(6 months, subject level)
PD: 4.3 (0.6) (BL) to 3.9 (0.8) mm
(6 months, subject level)
Control
BI: 1.7 (0.9) (BL) to 1.4 (1.0)














Table 6 Included studies—nonsurgical treatment of peri-implantitis: alternative measures for biofilm removal (Continued)
PD: 6.2 (1.6) (BL) to 6.3 (2.2) mm
(6 months, subject level)
No significant differences
between groups
Renvert et al. [30] RCT,
parallel
42 patients PD ≥5 mm, BOP + and/or
pus
6 months OHI + air abrasive device,
glycine powder
OHI + Er:YAG laser device






Bone loss >3 mm PD changes: 0.9 (0.8) mm
(6 months, implant level)
Radiographic bone level change:
−0.3(0.9) mm (6 months, subject
level)
Positive treatment outcome: 47 %
Control
PD changes: 0.8 (0.5) mm
(6 months, implant level)
Radiographic bone level change:
−0.1(0.8) mm (6 months, subject
level)
Positive treatment outcome: 44 %
No significant differences
between groups




32 patients (BL) PD ≥4 mm, BOP + with
suppuration
12 months OHI + air abrasive device,
glycine powder
OHI + mechanical debridement
(carbon curettes + 0.1 % CHX)
Test
25 patients (12 months) Bone loss ≤33 % BOP: 99.0 (4.1) (BL) to 57.8 (30.7) %
(12 months, subject level)
36 implants PD: 3.7 (1.0) (BL) to 3.2 (1.1) mm
(12 months, subject level)
8 implant systems Control
BOP: 94.7 (13.7) (BL) to 78.1
(30.0) % (12 months, subject level)
PD: 3.9 (1.1) (BL) to 3.5 (1.2) mm
(12 months, subject level)
BOP: significant difference
between groups at 3, 6 and
12 months














Table 7 Included studies—nonsurgical treatment of peri-implantitis: adjunctive antiseptic therapy











6 months OHI + ultrasonic debridement
+matrix containing 2.5-mg










Repeated application at sites
with PD ≥6 mm at 2, 4, 6, 8,
12 and 18 weeks
Repeated application at
sites with PD ≥6 mm at
2, 4, 6, 8, 12 and
18 weeks



















6 months not sign.
different between
groups
BL baseline, BOP bleeding on probing, CHX chlorhexidine digluconate, OHI oral hygiene instructions, PD probing pocket depth, RCT randomized controlled
clinical study
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antiseptic therapy using CHX. The application of this
specific air abrasive device was not associated with any
emphysema formation or complications in peri-implant
wound healing [27, 33]. At more advanced sites,
Er:YAG laser monotherapy and glycine powder air pol-
ishing resulted in comparable BOP/PD reductions and
crestal bone level changes, but failed to reduce bacterial
load [36] (Table 6).
Adjunctive antiseptic therapy One multicenter RCT
reported on the adjunctive antispective therapy to ultra-
sonic debridement (Table 7). In particular, a CHX con-
taining matrix was repeatedly applied at 2, 4, 6, 8, 12
and 18 weeks until PD was reduced to ≤5 mm. At
6 months, CHX chips resulted in a significantly higher
PD reduction than the placebo chips [23].
Adjunctive antibiotic therapy Three RCTs reported on
the adjunctive local antibiotic therapy to mechanical de-
bridement (Table 8). In particular, minocycline micro-
spheres were either applied once [32] at baseline or
repeatedly [29] at 30 and 90 days and compared with
local antispectic therapy using CHX gel (1.0 %). At
12 months, minocycline was associated with significantlyhigher BOP (refers to a repeated application) and PD
(refers to a single application) reductions when com-
pared with the control group. The radiographic (refers
to a repeated application) and microbiological analyses
failed to reveal any significant differences between both
groups. Similar clinical outcomes were also noted when
doxycycline hyclate was used as an adjunct to mechan-
ical debridement [26].
In one RCT, adjunctive local antibiotic therapy (mino-
cycline microspheres) was compared to adjunctive anti-
microbial photodynamic therapy. At 12 months, both
test and control groups were associated with significant
but comparable clinical, microbiological and immuno-
logical improvements [34, 37] (Table 8).
The weighted mean (WM) BOP and PD reductions
following conventional nonsurgical treatment (referring
to the control groups in respective studies) [23–27]
amounted to 31.12 % [SE = 9.14; 95 % CI (12.20, 49.05)]
and 0.71 mm [SE = 0.32; 95 % CI (0.07, 1.35)], respect-
ively. The weighted mean (WM) BOP and PD reductions
for alternative/adjunctive measures (i.e. air polishing,
aPDT, CHX chip, doxycycline, Er:YAG laser) [23–27]
amounted to 42.85 % [SE = 9.24; 95 % CI (24.70, 60.97)]
and 0.87 mm [SE = 0.29; 95 % CI (0.29, 1.44)],
respectively.
Table 8 Included studies—nonsurgical treatment of peri-implantitis: adjunctive antibiotic therapy





28 patients PD >5 mm 18 weeks OHI + mechanical debridement
(plastic curettes) + 0.2 % CHX
pocket irrigation + 8 %
doxycycline hyclate
OHI +mechanical debridement





Bone loss >50 % BOP: 0.54 (0.07) (BL) to 0.27 (0.06) %
(18 weeks, subject level)
PD: 5.64 (0.32) (BL) to 4.49 (0.29) mm
(18 weeks, subject level)
Control
BOP: 0.63 (0.06) (BL) to 0.50 (0.07) %
(18 weeks, subject level)
PD: 5.68 (0.28) (BL) to 5.4 (0.34) mm
(18 weeks, subject level)






32 patients PD ≥4 mm, BOP
+ with
suppuration
12 months OHI + mechanical debridement
(scalers + rubber cup + polishing)
+ 1 mg minoycycline microspheres
OHI +mechanical debridement
(scalers + rubber cup + polishing)







BOP: 88 (12) (BL) to 71 (22) %




PD: 3.9 (0.7) (BL) to 3.6 (0.6) mm
(12 months, subject level)
Control
BOP: 86 (14) (BL) to 78 (13) %
(12 months, subject level)
PD: 3.9 (0.3) (BL) to 3.9 (0.4) mm
(12 months, subject level)
PD reductions at 12 months sign.
higher in the test group
Comparable microbiological





32 patients PD ≥4 mm, BOP
+ with
suppuration
12 months OHI + mechanical debridement +
1 mg minoycycline microspheres
OHI +mechanical debridement +






Treatment was repeated at
days 30 and 90
Treatment was repeated at
days 30 and 90
BOP: 86.5 (20.1) (BL) to 48.1 (20.7) %




PD: 3.85 (1.04) (BL) to 3.55 (0.98) mm














Table 8 Included studies—nonsurgical treatment of peri-implantitis: adjunctive antibiotic therapy (Continued)
Radiographic bone levels: 0.77 (0.85)
(BL) to 0.7 (0.85) mm (12 months,
implant level)
Control
BOP: 89.2 (17.2) (BL) to 63.5 (19.2) %
(12 months, implant level)
PD: 3.87 (1.16) (BL) to 3.72 (1.02) mm
(12 months, implant level)
Radiographic bone levels: 0.41 (0.7) (BL)
to 0.46 (0.76) mm (12 months, implant
level)
BOP reductions at 12 months sign.
higher in the test group
Comparable microbiological






40 patients PD = 4–6 mm,
BOP + bone loss
= 0.5–2 mm
12 months OHI + mechanical debridement
(titanium curettes + glycin powder
air polishing, pocket irrigation using
3 % hydrogen peroxide) + aPDT
(660 nm, phenothiazine chloride dye)
OHI +mechanical debridement
(titanium curettes + glycin powder
air polishing, pocket irrigation using





BOP change: 57 % (12 months, subject
level)
PD changes: 0.56 mm (12 months,
subject level)
Complete resolution of mucosal
inflammation: 31.6 %
Control
BOP change: 65 % (12 months, subject
level)
PD changes: 0.11 mm (12 months,
subject level)
Complete resolution of mucosal
inflammation: 35.0 %
No significant differences in clinical,
microbiological and immunological
parameters between groups














Table 9 Included studies—surgical treatment of peri-implantitis: alternative measures for surface decontamination





32 patients PD ≥5 mm, BOP +
progressive vertical
bone loss
5 years OHI + open flapa surgery +
air polishing + carbon dioxide
laser (cw mode, 2.5 W, 12 × 5 s)
decontamination + soft tissue resection
OHI + open flapb surgery +





SBI: 0.6 (0.3) (BL) to 1.8 (1.1)
(48 months, implant level)
PD: 6.1 (1.6) (BL) to 3.4 (1.5)
mm (48 months, implant
level)
Control
SBI: 0.7 (0.8) (BL) to 1.1 (1.2)
(48 months, implant level)
PD: 5.1 (1.3) (BL) to 4.3 (1.2)








30 patients PD ≥5 mm, BOP +
and/or suppuration
12 months OHI/mechanical debridement +
resective therapy (apical
re-positioned flap + bone
re-contouring) + surface
debridement using surgical
gauzes soaked in saline +
decontamination using 0.12 %




re-positioned flap + bone
re-contouring) + surface
debridement using surgical gauzes






Bone loss ≥2 mm BOP: 80.4 (26.5) (BL) to 60.5
(30.1) % (12 months, implant
level)
PD: 6.6 (1.6) (BL) to 4.3 (2.1)
mm (12 months, implant
level)
MBL: 4.3 (2.1) (BL) to 5.0 (2.5)
mm (12 months, implant
level)
Control
BOP: 79.7 (28.1) (BL) to 57.2
(29.0) % (12 months, implant
level)
PD: 5.5 (1.4) (BL) to 3.7 (0.8)















Table 9 Included studies—surgical treatment of peri-implantitis: alternative measures for surface decontamination (Continued)
MBL: 3.6 (1.9) (BL) to 3.9 (2.0)
mm (12 months, implant
level)
No sign. differences in BOP
and PD reductions between
groups




44 patients PD ≥5 mm, BOP +
and/or suppuration
12 months OHI/mechanical debridement +
resective therapy (apical
re-positioned flap + bone
re-contouring) + surface
debridement using surgical
gauzes soaked in saline +
decontamination using 0.12 %
CHX + 0.05 % cetylpyridinium chloride
OHI/mechanical debridement +
resective therapy (apical
re-positioned flap + bone
re-contouring) + surface
debridement using surgical
gauzes soaked in saline +





Bone loss ≥2 mm BOP: 82.1 (23.9) (BL) to 42.7
(34.2) % (12 months, implant
level)
PD: 4.7 (1.0) (BL) to 3.0 (0.7)
mm (12 months, implant
level)
MBL: 4.0 (1.5) (BL) to 4.3 (1.7)
mm (12 months, implant
level)
Control
BOP: 74.2 (27.8) (BL) to 37.0
(35.5) % (12 months, implant
level)
PD: 5.0 (1.2) (BL) to 2.9 (0.7)
mm (12 months, implant
level)
MBL: 4.1 (1.6) (BL) to 4.1 (1.7)
mm (12 months, implant
level)
No sign. differences in BOP




















16 patients PD ≥6 mm, BOP +
and/or suppuration
6 months Mechanical debridement + open flap
surgery +mechanical debridement
(plastic curettes) and cotton swabs
soaked in saline
Mechanical debridement +
open flap surgery +mechanical
debridement (plastic curettes)
and cotton swabs soaked in
saline + 980 nm diode laser
application
Test
16 implants Radiographic bone
loss ≥2 mm
BOP: 81.2 (BL) to 23.8 %
(6 months, implant level)
PD: 5.92 (BL) to 4.44 mm
(6 months, implant level)
Control
BOP: 81.2 (BL) to 23.8 %
(6 months, implant level)
PD: 5.52 (BL) to 4.31 mm
(6 months, implant level)
Sign. BOP and PD reductions
in both groups at 6 months
BL baseline, BOP bleeding on probing, CCT non-randomized controlled clinical study, CHX chlorhexidine digluconate, MBL marginal bone level, OHI oral hygiene instructions, PD probing pocket depth, RCT randomized
controlled clinical study, SBI sulcus bleeding index
aSubgroup analysis of n = 17 implants














Table 10 Included studies—surgical treatment of peri-implantitis: adjunctive resective therapy


























zole + tetracycline hydro
chloride (3 min) + implanto












































BL baseline, BOP bleeding on probing, MBL marginal bone loss, PD probing pocket depth, RCT randomized controlled clinical study
aAll patients of the control group were discontinued from the study due to persistent clinical signs of inflammation
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Twelve studies (18 publications) reported on the surgical
treatment of peri-implantitis, employing either alternative
measures for surface decontamination (3 RCTs and 1
CCT) [38–41], adjunctive resective (1 RCT) [42] or aug-
mentative (4 RCTs and 4 CCTs) [40, 43–55] therapy. In
these studies, peri-implantitis was commonly defined by
BOP and a radiographic bone level changes. However,
the thresholds used to assess bone loss revealed large
variations and defect configurations (i.e. supra-/intrabony
defects) [56] were rarely reported (Tables 9, 10 and 11).
Alternative measures for surface decontamination In
one CCT, Deppe et al. [40] assessed the clinical efficacy
of carbon dioxide laser decontamination used as anadjunct to resective flap surgery + air polishing (con-
trol). While the test treatment improved the clinical
outcomes over the control measure at 4 months, mean
SBI and PD values were comparable in both groups at
about 5 years (Table 9).
In further two studies, De Waal et al. [38, 39]
employed an open flap debridement using gauzes
soaked in sterile saline + bone re-contouring + apical
flap re-positioning and compared one test (0.12 %
CHX + 0.05 % cetylpyridinium chloride) and two con-
trol (placebo solution or 2.0 % CHX) measures for sur-
face decontamination. At 12 months, the test and both
control procedures were associated with marked but
comparable reductions in mean BOP and PD scores,
respectively. Furthermore, between group comparisons
Table 11 Included studies—surgical treatment of peri-implantitis: adjunctive augmentative therapy
Publication Design Population Case
definition





20 patients PD >6 mm,
BOP + and/
or pus











Open flap surgery + mechanical
debridement (plastic curettes) +
nanocrystalline hydroxyapatite paste
Open flap surgery + mechanical
debridement (plastic curettes) +
bovine-derived xenograft + native
collagen barrier membrane
BOP reduction: 32 %
(4 years, subject level)
PD reduction: 2.5 (0.9) mm
(4 years, subject level)
Control
BOP reduction: 51 % (4 years,
subject level)
PD reduction: 1.1 (0.3) mm
(4 years, subject level)
BOP and PD reductions sign.










5 years Group 2 OHI + open flapa surgery + air
polishing + carbon dioxide laser
(cw mode, 2.5 W, 12 × 5 s)
decontamination + beta tricalcium
phosphate + cortical bone chips
harvested from the retromoar area
(50:50) + nonresorbable synthetic
barrier membrane
Group 4 OHI + open flapb surgery
+ air polishing + beta tricalcium
phosphate + cortical bone chips
harvested from the retromoar area










SBI: 0.5 (0.8) (BL) to 2.1 (1.4)
(48 months, implant level)
PD: 4.8 (1.4) (BL) to 2.5 (1.1) mm
(48 months, implant level)
Control
SBI: 1.2 (0.6) (BL) to 1.9 (1.0)
(48 months, implant level)
PD: 5.7 (1.4) (BL) to 2.5 (1.4) mm














Table 11 Included studies—surgical treatment of peri-implantitis: adjunctive augmentative therapy (Continued)







25 patients BOP + and/
or pus

















Open flap surgery + debridement +
decontamination using hydrogen
peroxide 3 % algae derived xenograft
+ resorbable synthetic barrier
membrane
Open flap surgery + debridement +
decontamination using hydrogen
peroxide 3 % algae derived
xenograft +
PD reduction: 3.0 (2.4) mm
(5 years, implant level)
Radiographic defect fill: 0.1 (0.5)
mm (5 years, implant level)
Control
PD reduction: 3.3 (2.0) mm
(5 years, implant level)
Radiographic defect fill: 0.1 (0.5)
mm (5 years, implant level)
Comparable defect fill and BOP










Circumferential-type (Ie) defects OHI
+ initial nonsurgical therapy
Buccal dehiscence-type defects













Open flap surgery + mechanical
debridement (carbon curettes) +
decontamination (cotton pellets
soaked in saline)
OHI + initial nonsurgical therapy
Open flap surgery + Mechanical
debridement (carbon curettes) +
decontamination (cotton pellets
soaked in saline)
BOP reduction: 38.9 (16.6) %




Bovine-derived xenograft + native
collagen barrier membrane
Bovine-derived xenograft + native
collagen barrier membrane
PD reduction: 1.6 (0.9) mm
(12 months, subject level)
Test Ic
BOP reduction: 25.9 (14.7) %
(12 months, subject level)
PD reduction: 1.6 (0.7) mm
(12 months, subject level)
Control Ie
BOP reduction: 61.1 (16.7) %














Table 11 Included studies—surgical treatment of peri-implantitis: adjunctive augmentative therapy (Continued)
PD reduction: 2.7 (0.7) mm
(12 months, subject level)
Sign. difference in BOP





26 patients PD ≥6 mm 12 months nonsubmerged
healing simultaneous connective
tissue graft at sites lacking
keratinized mucosa systemic
antibiotic medication (amoxicillin
+ clavulanic acid for 6 days)










OHI OHI BOP reduction: 60.4 %
(12 months, subject level)
Open flap surgery + mechanical
debridement (plastic curettes) +
decontamination (24 % EDTA and 1 %
CHX gel) + bovine-derived xenograft
Open flap surgery + mechanical
debridement (plastic curettes) +
decontamination (24 % EDTA and
1 % CHX gel) + bovine-derived
xenograft
PD reduction: 3.4 (1.7) mm
(12 months, subject level)
Radiographic defect fill: 1.9 (1.3)
mm (12 months, subject level)
Control
BOP reduction: 33.9 %
(12 months, subject level)
PD reduction: 2.1 (1.2) mm
(12 months, subject level)
Radiographic defect fill: 1.6 (0.7)
mm (12 months, subject level)
BOP and PD reductions sign.



















17 patients PD >6 mm,
BOP + and/
or pus











Open flap surgery + debridement +
decontamination using an Er:YAG
laser device (cone-shaped glass fibre
tip) at 11.4 J/cm2 implantoplasty at
bucally and supracrestally exposed
implant parts
Open flap surgery + Mechanical
debridement (plastic curettes) +
decontamination (cotton pellets
soaked in saline) implantoplasty at
bucally and supracrestally exposed
implant parts
BOP reduction: 71.6 (24.9) %




Bovine-derived xenograft + native
collagen barrier membrane at
intrabony components
Bovine-derived xenograft + native
collagen barrier membrane at
intrabony components
PD reduction: 1.3 (1.8) mm
(4 years, subject level)
Control
BOP reduction: 85.2 (16.4) %
(4 years, subject level)
PD reduction: 1.2 (1.9) mm
(4 years, subject level)
BOP and PD reductions












Open flap surgery + mechanical
debridement (titanium instruments) +
decontamination using hydrogen
peroxide 3 % cortical bone chips
harvested from the mandibular ramus
+ resorbable synthetic barrier
membrane
Open flap surgery + mechanical
debridement (titanium
instruments) + decontamination
using hydrogen peroxide 3 %
bovine-derived xenograft + resorba-









BOP reduction: 44.8 (6.3) %





PD reduction: 2.0 (0.3) mm
(12 months, implant level)
Radiographic bone level gain: 0.2
(0.3) mm (12 months, implant
level)
Control
BOP reduction: 50.4 (5.3 %)
(12 months, implant level)
PD reduction: 3.1 (0.2)mm














Table 11 Included studies—surgical treatment of peri-implantitis: adjunctive augmentative therapy (Continued)
Radiographic bone level gain: 0.8
(0.4) mm (12 months, implant
level)
PD reductions and bone level
gains were significantly higher at
control sites
Wohlfahrt
et al. [55, 58]
RCT,
parallel






healing for 6 months
Open flap surgery + mechanical
debridement (titanium curettes) +
conditioning using 24 %
ethylenediaminetetraacetic acid gel
(2 min) + augmentation of intrabony
defect components using porous
titanium granules
Open flap surgery + mechanical
debridement (titanium currettes) +









BOP reduction: 0.38 (2.1) %
(12 months, implant level)
PD reduction: 1.7 (1.7) mm
(12 months, implant level)
Radiographic defect fill: 57.0
(45.1) % (12 months, implant
level)
Control
BOP reduction: 0.56 (2.9) %
(12 months, implant level)
PD reduction: 2.0 (2.3) mm
(12 months, implant level)
Radiographic defect fill: −14.8
(83.4) % (12 months, implant
level) no sign. reductions in BOP
scores in both groups
comparable reductions in MMP-8
and bone level markers
BL baseline, BOP bleeding on probing, CCT non-randomized controlled clinical study, CHX chlorhexidine dugluconate, MMP-8 matrixmetalloproteinase-8, PD probing pocket depth, RCT randomized controlled clinical
study, SBI sulcus bleeding index, SLA sand blasted and acid etched, TPS titanium plasma flamed
aSubgroup analysis of n = 11 implants
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marginal bone loss after therapy [38, 39]. Similarly,
Papadopoulos et al. [41] also failed to reveal any sig-
nificant clinical improvements in mean BOP and PD
scores at 6 months, when a 980-nm diode laser was
used as an adjunct to mechanical open flap debride-
ment (Table 9).
Adjunctive resective therapy One study assessed the
clinical efficacy of an implantoplasty (diamond/arkan-
sas burs + silicone polishers) when used as an adjunct
to open flap debridement + bone re-contouring + apical
flap re-positioning [42]. At 24 months, all patients from
the control group had to be discontinued from the
study due to persistent active signs of peri-implant in-
flammation. This was associated with elevated mBI and
PD scores when compared with the test group. On the
contrary, resective therapy resulted in significantly
higher mean mucosal recessions (1.64 ± 1.29 vs. 2.3 ±
1.45 mm) but no pseudopocket formation [42], while
test sites were associated with stable radiographic bone
levels at 3 years, the interproximal bone loss at control
sites amounted to 1.45–1.54 mm [57] (Table 10).
The calculated WM BOP [38, 39, 55] and PD [38–40, 55]
reductions following surgical treatment (i.e. open flap with
and without soft tissue resection) amounted to 34.81 %
[SE = 8.95; 95 % CI (17.25, 52.37)] and 1.75 mm [SE =
0.34; 95 % CI (1.08, 2.42)].
Adjunctive augmentative therapy The clinical efficacy
of adjunctive augmentative therapy to open flap de-
bridement (titanium curettes + conditioning using 24 %
ethylenediaminetetraacetic acid gel + submerged heal-
ing for 6 months) was merely assessed in one study
[55]. Notably, 12/16 control and 13/16 test sites re-
vealed a premature exposure during the submerged
healing phase of 6 months. At 12 months after therapy,
the application of porous titanium granules to the
intrabony defect components resulted in a significantly
higher percentage of radiographic defect fill when com-
pared with open flap surgery alone. Moreover, the test
group was associated with an increase in implant stabil-
ity quotient, whereas these values further decreased at
control sites. However, both groups revealed compar-
able PD reductions and only minor improvements in
mean BOP scores [55]. The immunological analysis did
not reveal any significant between differences in the
reduction of MMP-8 levels or bone level markers [58]
(Table 11). Four RCTs and four CCTs compared differ-
ent augmentation protocols employing various methods
for surface decontamination, bone fillers (i.e. alloplas-
tic, xenogenic, autogenous) and barrier membranes
(synthetic, native collagen) over a period of up to
5 years [40, 43–55]. The majority of these studiesconsidered PD and BOP reductions as primary out-
comes but also reported on radiographic defect fill
(Table 11).
WM BOP [43, 49, 51, 53, 55] and PD [40, 43–55] reduc-
tions following adjunctive augmentative therapy amounted
to 50.73 % [SE = 3.5; 95 % CI (43.87, 57.59)] and 2.20 mm
[SE = 0.22; 95 % CI (1.76, 2.64)], respectively. The out-
comes of therapy was mainly influenced by the type of
bone filler (i.e. a slowly resorbing bovine-derived mineral
was superior to autogenous bone and an alloplastic mater-
ial), defect characteristics (i.e. circumferential-type defects
were superior to dehiscence-type defects) and implant
surface characteristics (i.e. moderately rough surfaces were
superior to rough surfaces) (Table 11).Meta-analysis
Meta-analysis to estimate the weighted mean difference
(WMD) between test and control treatments was con-
ducted on RCTs reporting on similar assessments of
either absolute BOP or PD scores.Nonsurgical treatment of peri-implant mucositis—
adjunctive antiseptics/antibiotics Based on four and
four studies, WMD in BOP [16, 17, 19, 22] and PD
[17, 19, 20, 22] scores amounted to −8.16 % [SE = 4.61;
p > 0.05; 95 % CI (−17.20, 0.88)] and −0.15 mm [SE =
0.13; p > 0.05; 95 % CI (−0.42, 0.11)], not favouring local
antiseptic or antibiotic (i.e. local and systemic) therapy as
an adjunct to mechanical debridement (p value for hetero-
geneity: 0.42, I2 = 0.0 % = low heterogeneity; p value for
heterogeneity: 0.45, I2 = 0.0 % = low heterogeneity, re-
spectively) (Fig. 2a, b).
Egger’s linear regression method revealed symmetrical
plots for changes in BOP (p = 0.51) and PD (p = 0.69)
thus suggesting the absence of publication bias.Nonsurgical treatment of peri-implantitis—alterna
tive methods for biofilm removal Based on three stud-
ies [24, 25, 27], WMD in BOP scores between test
and control groups amounted to −23.12 % [SE = 4.81;
p < 0.001; 95 % CI (−32.56, −13.69)] favouring alternative
methods (i.e. Er:YAG laser, glycine air polishing,) for bio-
film removal over mechanical debridement (p value for
heterogeneity: 0.55, I2 = 0.0 % = low heterogeneity; 0.39)
(Fig. 3a). Based on five studies [24, 25, 27, 28, 31], WMD
in PD scores between test and control groups amounted
to −0.49 mm [SE = 0.21; p < 0.05; 95 % CI (−0.91, −0.08)]
not favouring alternative methods (i.e. Er:YAG laser,
glycine air polishing, ultrasonic system) for biofilm re-
moval over mechanical debridement (p value for hetero-
geneity: 0.029, I2 = 62.8 % = substantial heterogeneity;
0.39) (Fig. 3b).
Fig. 2 Forest plot indicating weighted mean difference (95 % CI) in the reduction of primary outcomes following nonsurgical treatment of peri-
implant mucositis. a Adjunctive antiseptic/antibiotic therapy—BOP. b Adjunctive antiseptic/antibiotic therapy—PD
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plots for changes in BOP (p = 0.41) and PD (p = 0.39)
thus suggesting the absence of any publication bias.Nonsurgical treatment of peri-implantitis—adjunctive
antiseptic/antibiotic therapy Based on four studies
[23, 26, 29, 32], WMD in BOP scores between test and
control groups amounted to −16.53 % [SE = 4.41; p < 0.001;
95 % CI (−25.18, −7.89)] favouring local antibiotic therapy
as an adjunct to mechanical debridement (p value for het-
erogeneity: 0.113, I2 = 49.77 % =moderate heterogeneity)
(Fig. 3c). WMD in PD scores between test and control
groups amounted to −0.829 mm [SE = 0.51; p > 0.05;
95 % CI (−1.84, 0.18)] not favouring antiseptic/anti-
biotic therapy as an adjunct to mechanical debridement
(p value for heterogeneity: 0.000, I2 = 87.37 % = consid-
erable heterogeneity) (Fig. 3d).
Egger’s linear regression method revealed symmetrical
plots for changes in BOP (p = 0.17) and PD (p = 0.07)
thus suggesting the absence of any publication bias.Surgical treatment of peri-implantitis - alternative
measures for surface decontamination Based on two
studies [38, 39], WMD in BOP and PD scores between
test and control groups amounted to 5.61 % [SE = 7.68;
p > 0.05; 95 % CI (−9.44, 20.68)] and 0.22 mm [SE = 0.22;
p > 0.05; 95 % CI (−0.20, 0.65)] not favouring alternative
(i.e. CHX + CPC) over conventional (i.e. CHX) measures
for surface decontamination (p value for heterogeneity:
0.76, I2 = 0.0 % = low heterogeneity; 0.60, I2 = 0.0 % = low
heterogeneity, respectively) (Fig. 4a, b).
Discussion
The present systematic review and meta-analysis was
conducted to address the following focused question:
“In patients with peri-implant mucositis and peri-
implantitis, what is the efficacy of nonsurgical (i.e. re-
ferring to peri-implant mucositis and peri-implantitis)
and surgical (i.e. referring to peri-implantitis) treat-
ments with alternative or adjunctive measures on chan-
ging signs of inflammation compared with conventional
nonsurgical and surgical treatments alone?”.
Fig. 3 Forest plot indicating weighted mean difference (95 % CI) in the reduction of primary outcomes following nonsurgical treatment of
peri-implantitis. a Alternative measures for biofilm removal—BOP. b Alternative measures for biofilm removal—PD. c Adjunctive antibiotic
therapy—BOP. d Adjunctive antiseptic/antibiotic therapy—PD
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Fig. 4 Forest plot indicating weighted mean difference (95 % CI) in the reduction of primary outcomes following surgical treatment of peri-implantitis.
a Alternative measures for surface decontamination—BOP. b Alternative measures for surface decontamination—PD
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studies considered appropriate test and control treat-
ments needed to address the aforementioned focused
question. In particular, this was true for 8 (7 RCTs and 1
CCT) [15–22] and 9 (9 RCTs) [23–26, 28, 29, 31–33]
studies reporting on the nonsurgical treatment of peri-
implant mucositis and peri-implantitis, as well as 5 RCTs
[38, 39, 41, 42, 55] reporting on the surgical treatment
of peri-implantitis. In addition, 5 RCTs and 4 CCTs not
implementing appropriate control measures (i.e. mech-
anical/ultrasonic debridement or open flap debridement
alone) but reporting on changes in primary outcomes
were included for the estimation of the overall efficacy
(referring to WM changes in BOP and PD scores) of
nonsurgical [30, 34] and surgical [40, 43, 44, 46, 48, 52, 53]
treatments of peri-implantitis. Moreover, it must be em-
phasized that the percentage across all included studies
for high risk of bias items was 34.1 %, thus pointing to
a need to improve the quality of reporting in future
studies.
Within these limitations, the current data synthesis
revealed that for the nonsurgical treatment of peri-
implant mucositis, WMD in BOP [16, 17, 19, 22] and
PD [15, 17, 19, 20, 22] scores amounted to −8.16 % and
−0.15 mm, not favouring local antiseptic or antibiotic
(i.e. local and systemic) therapy as an adjunct to mech-
anical debridement alone. Basically, these data corrob-
orate the findings of a recent systematic review and
meta-analysis, also indicating that adjunctive therapymay not improve the efficacy of professionally adminis-
tered plaque removal in reducing BOP (i.e. local anti-
septic or local/systemic antibiotics), GI and PD (i.e.
local antiseptics, systemic antibiotics, air abrasive de-
vice) scores at mucositis sites [9]. When considering the
present narrative data synthesis on the adjunctive [15] or
alternative use of glycine powder air polishing [21], it was
also noted that this device did not reveal any major im-
provements in BI/BOP scores or disease resolution over
the respective control measures. In this context, it must
be emphasized that BOP is the key parameter for the diag-
nosis of peri-implant mucositis [1], and the “resolution of
peri-implant mucosal inflammation as evidenced by the
absence of BOP” was the suggested endpoint following
nonsurgical treatment of mucositis lesions [13]. All these
data, taken together with the present findings support the
view that OHI and mechanical debridement with or with-
out polishing tools may be defined as a current standard
of care for the management of peri-implant mucositis [6].
In contrast, for the nonsurgical treatment of peri-
implantitis, WMD in BOP scores amounted to −16.53 %
[23, 26, 29, 32] and 23.12 % [24, 25, 27], thus favouring
either adjunctive local antibiotic therapy or alternative
measures for plaque removal (i.e. Er:YAG laser or glycine
powder air polishing) over respective control treatments.
However, these improvements were not observed when
analysing WMD in PD scores between test and control
groups. Basically, these observations were also supported
by the differences in the estimated WM BOP (31.12 vs.
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lowing nonsurgical treatment of peri-implantitis using
either conventional [23–27] or alternative/adjunctive mea-
sures (i.e. air polishing, aPDT, CHX chip, doxycycline,
Er:YAG laser) [23–27], respectively.
Since the suggested endpoint following nonsurgical
treatment of peri-implantitis is a “composite outcome of
disease resolution including the absence of deep PD with
bleeding and suppuration” [13], one has to critically
emphasize the limited efficacy at “deep sites”. In particular,
several studies reported on increasing BOP scores between
3 and 12 months following nonsurgical treatment of “se-
vere” peri-implantitis sites using either mechanical de-
bridement, adjunctive aPDT, Er:YAG laser monotherapy
or glycine powder air polishing. The efficacy of all treat-
ment procedures investigated was higher at “moderately”
deep sites [24, 27, 33, 59]. In this context, however, one
also has to realize that PD scores at implant sites may be
influenced by a variety of different local factors, including
the soft tissue thickness, vertical implant positioning, or a
specific design of the implant-abutment connection (e.g.
platform-switching). Accordingly, the classification of a
“deep” pocket needs to be accomplished on an individual
basis and disease severity should also consider “propor-
tions of affected implants per patient in the presence of
multiple implants” [6].
When further analysing the present results, it was also
noted that nonsurgical treatment of peri-implantitis
commonly failed to result in major microbiological im-
provements [32, 34–37], thus potentially explaining the
frequency of residual BOP scores at respective sites.
At the time being, there is a lack of clinical studies aimed
at comparing the efficacy of nonsurgical and surgical
treatments of peri-implantitis. However, a preclinical study
employing the ligature model has indicated that open flap
debridement was associated with significant histological
improvements in osseous defect fill and establishment of a
new bone-to-implant when compared with nonsurgical
treatments. The latter outcome was mainly influenced by
the method of surface decontamination [60]. Accordingly,
a “proven method of decontaminating the implant surface”
has been defined as a critical component in surgical
therapy [13]. However, the present qualitative and quanti-
tative analysis has indicated that the clinical, radiographical
and microbiological outcomes following either open flap
debridement or surgical augmentative therapy were not
influenced by the decontamination protocol, including
chemical or photothermal (i.e. carbon dioxide, diode- or
Er:YAG laser radiation) approaches [38–41, 49, 50, 52].
Moreover, two RCTs [38, 39] reported on an additional
bone loss at 6 and 12 months after open flap debridement,
thus indicating that disease resolution (i.e. “absence of deep
probing pocket depths with bleeding and suppuration and
no additional bone loss”) [13] was commonly not achieved.The present data synthesis also revealed a lack of
RCTs/CCTs implementing appropriate test and control
groups to assess the efficacy of adjunctive resective or
augmentative measures over open flap debridement
alone. The available studies have indicated that resective
surgery (i.e. apical re-positioned flap + bone contouring)
+ implantoplasty was more effective in obtaining and
maintaining disease resolution over resective surgery
alone [42, 57]. In contrast, surgical augmentative therapy
of the intrabony defect component using porous titan-
ium granules was associated with a significantly higher
radiographic defect fill, but failed to improve a reduction
in mean BOP and PD scores over the control treatment
[55]. When considering the estimated WM BOP (50.73
vs. 34.81 %) [38, 39, 43, 49, 51, 53, 55] and PD (2.20 vs.
1.75 mm) [38–40, 43–55] reductions, the clinical out-
comes obtained following adjunctive augmentative ther-
apy tended to be improved when compared with
surgical measures alone. However, it has to be realized
that for the data synthesis in the latter group, surgical
procedures with and without soft tissue resection were
combined, and therefore, the interpretation of the over-
all performance of surgical measures without augmenta-
tive measures on PD reductions is difficult. Moreover,
obvious variations in the surgical procedures, including
different decontamination protocols, administration of
prophylactic systemic antibiotics, and modes of healing
(i.e. open vs. submerged) may not allow for a direct
comparison of these estimated outcomes. Basically, the
estimated WM BOP and PD reductions corroborate
those calculations reported in a recent systematic review
on reconstructive procedures for the management of
peri-implantitis. When also case series were included in
the meta-analysis, these values amounted to 45.8 and
2.97 mm [61]. Furthermore, the present qualitative ana-
lysis of the available data on surgical augmentative therapy
have indicated, that the outcomes of therapy may be influ-
enced by several local factors, mainly including the physico-
chemical properties of the bone filler [43, 48, 51, 54], the
defect configuration [53], as well as implant surface charac-
teristics [44]. Any beneficial effect of a resorbable
synthetic barrier membrane could not be identified
[45–47]. Nevertheless, the available evidence did not
allow for any conclusive statements on the potential
superiority of any particular augmentation protocol.
Finally, it must be emphasized that laser therapy, the
application of bone grafts and barrier membranes were re-
ported to be associated with the highest cost-effectiveness
ratio (i.e. costs and proportions of lost implants) among
11 treatment procedures investigated [62].
Conclusions
While OHI +mechanical debridement alone was found to
be effective for the management of peri-implant mucositis,
Schwarz et al. International Journal of Implant Dentistry  (2015) 1:22 Page 32 of 34alternative/adjunctive measures may improve the efficacy
over/of conventional treatments at peri-implantitis sites.
Adjunctive resective and/or augmentative measures are
promising; however, their beneficial effect on the clin-
ical outcome of surgical treatments needs to be further
investigated.
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